10-K: TherapeuticsMD Transforms into Royalty Company, Reports Full Year 2023 Results

TherapeuticsMD transitioned to a pharmaceutical royalty company in 2022, licensing its products and reporting a net loss of $10.3 million for 2023.

Summary

• TherapeuticsMD completed its transformation into a pharmaceutical royalty company in December 2022, licensing its key products to Mayne Pharma.
• The company's 2023 revenue was $1.3 million, primarily from royalties, a significant decrease from $70 million in 2022 which included upfront payments.
• TherapeuticsMD reported a net loss of $10.3 million for 2023, compared to a net income of $112 million in 2022, which was boosted by the Mayne transaction and vitaCare divestiture.
• The company's operating expenses decreased to $9.8 million in 2023 from $67.4 million in 2022 due to the shift in business model.
• The company's cash and cash equivalents totaled $4.3 million as of December 31, 2023.
• TherapeuticsMD is dependent on third parties achieving specified milestones and product sales for revenue.
• The company has a minimum annual royalty agreement with Mayne Pharma of $3 million per year for 12 years, adjusted for inflation at an annual rate of 3%.
• The company has a working capital dispute with Mayne Pharma regarding payer rebates and wholesale distributor fees, which could impact future financials.
• The company has a going concern warning due to its current liquidity position and the uncertainty of future financing.

Sentiment

Score: 3

Explanation: The document presents a challenging financial situation with a significant drop in revenue and a net loss. The going concern warning and working capital dispute add to the negative outlook, despite the strategic shift to a royalty model.

Positives

• The company successfully transitioned to a royalty-based business model.
• Operating expenses were significantly reduced due to the change in business model.
• The company has a minimum annual royalty agreement with Mayne Pharma, providing a stable revenue stream.
• The company has potential for additional revenue through milestone payments from Mayne Pharma.

Negatives

• The company reported a net loss of $10.3 million for 2023.
• Revenue decreased significantly from $70 million in 2022 to $1.3 million in 2023.
• The company has a working capital dispute with Mayne Pharma, which could impact future financials.
• The company has a going concern warning due to its current liquidity position.

Risks

• The company's revenue is dependent on the sales performance of its licensees.
• The company may need to raise additional capital to fund operations.
• The company faces a working capital dispute with Mayne Pharma.
• The company's ability to continue as a going concern is uncertain.
• The company is dependent on third-party manufacturers for its licensed products.
• The company faces competition from branded and generic products.
• The company's success is tied to the distribution channels of its licensees.
• The company may face challenges in protecting its intellectual property.
• The company's stock price may be volatile.

Future Outlook

The company's future performance is dependent on the sales of its licensed products by Mayne Pharma and other partners, as well as its ability to manage its finances and resolve the working capital dispute. The company may need to raise additional capital to fund operations.

Management Comments

• Management continues to monitor the unresolved and pending net working capital items as changes to estimated amounts owed or amounts due from Mayne Pharma that may be material.
• Management believes its estimated allowances for payer rebates and wholesale distributor fees are reasonable and intends to resolve this matter through the process outlined in the Transaction Agreement.

Industry Context

The transition to a royalty company reflects a strategic shift in the pharmaceutical industry, where companies are increasingly focusing on licensing and partnerships to leverage commercial capabilities. This move allows TherapeuticsMD to focus on its core competencies while generating revenue from its intellectual property.

Comparison to Industry Standards

• The transition to a royalty model is similar to other pharmaceutical companies that have divested commercial operations to focus on research and development or intellectual property management.
• The company's revenue is significantly lower than comparable pharmaceutical companies with commercial operations, but this is expected given the shift to a royalty model.
• The company's operating expenses are also lower than comparable companies, reflecting the reduced operational footprint.
• The company's cash position is relatively weak compared to other pharmaceutical companies, highlighting the need for additional financing.

Management Changes

Legal Proceedings

• The company is involved in a patent infringement lawsuit with Teva Pharmaceuticals regarding IMVEXXY.
• The company is involved in a breach of contract lawsuit with a former contractor.

Related Party Transactions

• The company has entered into subscription agreements with Rubric Capital Management LP, a significant stockholder.
• The company redeemed all outstanding shares of Series A Preferred Stock previously issued to affiliates of Rubric.

Stakeholder Impact

• Shareholders face the risk of dilution from potential future equity issuances.
• Employees were significantly impacted by the restructuring and workforce reduction in 2022.
• Customers of the company's products are now served by Mayne Pharma and other licensees.
• Creditors were repaid in full following the Mayne transaction.

Next Steps

• The company intends to resolve the working capital dispute with Mayne Pharma.
• The company may pursue various equity and debt financing and other alternatives to address its capital needs.
• The company will continue to monitor the sales performance of its licensed products.

Key Dates

Keywords

royalty company, pharmaceutical, licensing, Mayne Pharma, IMVEXXY, BIJUVA, ANNOVERA, net loss, revenue, working capital, going concern, milestone payments, minimum annual royalties